teriflunomide

INN (International Nonproprietary Name)

🇺🇸 Also approved in the US (FDA)

TERIFLUNOMIDE — NATCO, approved 2023-05-15 (ANDA209555).

Most reported adverse events (US / FAERS)

49,424 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

alopecia

6,069

multiple sclerosis relapse

5,225

fatigue

4,759

diarrhoea

4,752

Medicines containing this active substance

3 medicines

Teriflunomide Viatris (previously Teriflunomide Mylan)

🇺🇸 Also approved in the US (FDA)

TERIFLUNOMIDE — NATCO, approved 2023-05-15 (ANDA209555).

Most reported adverse events (US / FAERS)

49,424 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.

alopecia

6,069

multiple sclerosis relapse

5,225

fatigue

4,759

diarrhoea

4,752

fall

3,337

hypoaesthesia

3,170

headache

2,998

drug ineffective

2,819

paraesthesia

2,813

nausea

2,743

gait disturbance

2,487

pain

2,231

multiple sclerosis

2,217

condition aggravated

2,014

depression

1,790